← Back to Search

miRNA Modulation

miRNA for Systemic Inflammatory Response Syndrome

N/A
Waitlist Available
Led By Frederick A Willyerd, MD
Research Sponsored by Phoenix Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up duration of hospital stay, an expected average of 3 weeks
Awards & highlights

Study Summary

The goal of this study is to demonstrate the sensitivity and specificity of detecting circulating micro RNA (miRNA) biomarkers in pediatric septic patients. It will also follow expression and modulation of levels in response to therapy in comparison to current biomarkers.

Eligible Conditions
  • Systemic Inflammatory Response Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of hospital stay, an expected average of 3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of hospital stay, an expected average of 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Risk of Mortality
Secondary outcome measures
Organ Dysfunction
Organ Failure
Patient acuity

Trial Design

1Treatment groups
Experimental Treatment
Group I: miRNAExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Phoenix Children's HospitalLead Sponsor
74 Previous Clinical Trials
5,013,990 Total Patients Enrolled
Frederick A Willyerd, MDPrincipal InvestigatorPhoenix Children's Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby May 2025